Royalty Pharma plc (RPRX) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 3 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Wed, May 6, 2026before open 36 8-K
Q4 FY2025Wed, Feb 11, 2026before open 42 8-K
Q3 FY2025Wed, Nov 5, 2025before open 36 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Tue, Feb 11, 2025before open 42 8-K

What they guided beta

Q3 FY2026 "Document Press Release November 4, 2026 R oyalty Pharma reports third quarter 2026 results Portfolio Rece ipts growth o f 9% to $890 million ; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, NY, November 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts." exhibit
Q3 FY2026 "“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board." exhibit
Q3 FY2026 "Raising financial guidance for full year 2026 (excludes contribution from future transactions)" exhibit
Q3 FY2026 "Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%." exhibit
Q3 FY2026 "Royalty Pharma Press Release | November 4, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows: Provided November 4, 2026 Previous Portfolio Receipts $3,500 million to $3,550 million $3,400 million to $3,500 million Payments for operating and professional costs 5.5% to 6.0% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and " exhibit
Q2 FY2026 "Document Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised f ull year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, NY, August 5, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts." exhibit
Q2 FY2026 "Raising financial guidance for full year 2026 (excludes contribution from future transactions)" exhibit
Q2 FY2026 "Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,400 million and $3,500 million (previously $3,325 million to $3,450 million), representing expected Royalty Receipts growth of 7% to 10%." exhibit
Q2 FY2026 "Royalty Pharma Press Release | August 5, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows: Provided August 5, 2026 Previous Portfolio Receipts $3,400 million to $3,500 million $3,325 million to $3,450 million Payments for operating and professional costs 5.5% to 6.5% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Miles" exhibit
Q2 FY2026 "The above Portfolio Receipts guidance provided on August 5, 2026 includes expected Royalty Receipts growth of 7% to 10% in 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RPRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RPRX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RPRX earnings date badge

HTML

<a href="https://veritasdata.dev/company/RPRX/"><img src="https://veritasdata.dev/embed/RPRX.svg" alt="RPRX earnings date" width="240" height="56"></a>

Markdown

[![RPRX earnings date](https://veritasdata.dev/embed/RPRX.svg)](https://veritasdata.dev/company/RPRX/)

Script

<script async src="https://veritasdata.dev/embed/RPRX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RPRX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.